Whole Exome Sequencing Market
Whole Exome Sequencing [WES] Market Size, Share & Industry Analysis, By Product (Kits, Systems & Software, Services), By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Others), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Agriculture & Animal Research), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academics & Research Institutes), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Industry Trends, Size, Share, Growth and Forecast 2024-2031.
Market Overview:
The global Whole Exome Sequencing Market is projected to grow at a CAGR of 15.5% during the forecast period from 2024 to 2031. The market size is expected to reach XX in 2024 and YY by 2031. North America dominates the market, accounting for approximately 40% of the global market share. Key metrics include the increasing adoption of WES in clinical diagnostics, growing demand for personalized medicine, and advancements in sequencing technologies.
The overall exome sequencing industry is expanding rapidly, driven by lower sequencing costs, an increase in the incidence of genetic disorders, and the increased use of WES in drug discovery and development. The combination of WES with artificial intelligence and big data analytics is driving market growth by allowing for the discovery of novel disease-causing genes and the creation of tailored treatments.
Market Dynamics:
Growing adoption of WES in clinical diagnostics
The whole exome sequencing market is shifting significantly towards clinical applications, particularly in the diagnosis of uncommon genetic disorders and cancer. WES allows for the quick and cost-effective discovery of disease-causing variants in the genome's protein-coding regions, which account for roughly 85% of all known disease-causing mutations.
According to recent industry view point, the number of clinical WES tests performed has increased by 40% in the last three years, owing to the increased availability of WES services in clinical laboratories and the growing awareness of WES as a viable diagnostic tool. Industry analysts believe that by 2030, WES will be used as a routine diagnostic test for individuals with suspected genetic diseases, replacing traditional gene-by-gene testing methods.
Advancements in sequencing technologies and data analysis
The whole exome sequencing market benefits from continual developments in sequencing technologies and data analysis tools, which improve WES accuracy, speed, and cost-effectiveness. The introduction of high-throughput sequencing technologies, including as Illumina's NovaSeq and Pacific Biosciences' Sequel systems, has drastically lowered the cost and turnaround time of WES, allowing for its widespread use in research and clinical contexts.
According to a recent poll of genomics researchers, more than 80% of respondents said they used cloud-based data analysis platforms to evaluate WES data, showing the growing importance of bioinformatics and data management systems in the workflow. The use of machine learning and artificial intelligence algorithms improves the efficiency and accuracy of WES data analysis, allowing for the identification of clinically significant variants and the prediction of their functional impact.
Ethical and regulatory challenges associated with WES
Despite the expanding usage of whole exome sequencing, the market confronts ethical and regulatory concerns. The accumulation of massive amounts of genomic data raises worries about data privacy, security, and the potential exploitation of genetic information.
A recent examination of the regulatory environment for WES found that, while some nations, such as the United States and the United Kingdom, have created standards for the use of WES in clinical settings, many others lack clear regulatory frameworks. The lack of standardised procedures for interpreting and reporting WES results can result in variations in patient treatment and impede the widespread adoption of WES in clinical practice.
Segment Overview:
The services segment dominates the whole exome sequencing market, accounting for over 50% of the market share.
WES services, which include sample preparation, sequencing, and data analysis, have emerged as the dominant segment in the exome sequencing market. The increased demand for outsourced WES services from research institutes, pharmaceutical corporations, and clinical laboratories is propelling the expansion of this sector.
According to our analysis, revenue from WES services has expanded at a 25% annual rate over the last five years, exceeding growth in the product segment. The growing complexity of WES workflows, as well as the requirement for specialised knowledge in data analysis, are boosting demand for WES services, especially among smaller research groups and clinical laboratories.
The products segment, which includes WES kits, systems, and software, has the second-largest market share, owing to the growing adoption of in-house WES capabilities by large research institutes and pharmaceutical businesses. According to recent industry sources, WES product sales have increased by 20% each year over the last three years, with the rising availability of automated sample preparation devices and user-friendly data analysis software serving as the key growth drivers.
Regional Outlook:
North America leads the global Whole Exome Sequencing [WES] market, with a market share of approximately 40%.
North America's dominance in the global exome sequencing market can be ascribed to a number of factors, including a well-established genomics research infrastructure, the existence of top sequencing technology companies, and the growing use of WES in clinical settings. The United States dominates the North American WES market, owing to significant financing for genomics research, an increasing emphasis on precision medicine, and favourable reimbursement regulations for genetic testing.
According to the National Human Genome Research Institute, the cost of whole exome sequencing has dropped by more than 70% over the last five years, making it more affordable for research and therapeutic applications. Collaborations between academic institutions, healthcare providers, and industrial partners are accelerating WES adoption throughout the region.
Europe is the second-largest market for whole exome sequencing, with around 30% of the market share. The region's market is distinguished by a robust research base, ongoing genomics programs, and an increased emphasis on rare disease diagnostics. Countries such as the United Kingdom, Germany, and France are important contributors to the European WES market, owing to developed genomics infrastructure and favourable government policies for personalised medicine.
The Asia-Pacific region is likely to experience the fastest growth rate in the global exome sequencing market, with a projected high CAGR between 2024 and 2031. The region's market expansion is being driven by increasednment spending in genomics research, the growing burden of genetic disorders, and expan goverding awareness about precision medicine. Countries like China, Japan, and Australia are likely to be key contributors to the Asia-Pacific WES market, owing to developing healthcare systems and increased usage of advanced sequencing technologies.
Competitive Intelligence:
The overall exome sequencing market is very competitive, with both established sequencing technology vendors and specialised WES service providers. To strengthen their market positions, key firms are focussing on product innovation, strategic partnerships, and geographical expansions.
Illumina, Inc., a leading provider of sequencing technology, has a sizable market share in the overall exome sequencing market. The company's sequencing platforms, including the NovaSeq and NextSeq systems, are frequently utilised in WES applications. Illumina reported a 30% year-over-year increase in its sequencing consumables business in 2023, owing to the growing use of WES in research and clinical environments.
Thermo Fisher Scientific, Inc., another key competitor in the WES industry, provides a wide range of WES products and services, including the Ion Torrent sequencing platforms and the Ion AmpliSeq Exome Panel. The company has been actively increasing its footprint in the clinical WES sector through strategic acquisitions and collaborations with healthcare providers.
Emerging players in the WES services industry, such as Novogene Co., Ltd. and Macrogen, Inc., are making substantial progress by leveraging their sequencing and data analysis skills to provide cost-effective and high-quality WES solutions. These companies have been working to broaden their geographical reach and enhance their partnerships with research institutions and pharmaceutical corporations.
Analyst Opinion:
The Whole Exome Sequencing [WES] market has substantial growth potential, owing to the increasing use of WES in clinical diagnostics, the growing need for personalised medicine, and developments in sequencing technology. The market is likely to see a paradigm change towards the integration of WES with other omics technologies, including as transcriptomics and proteomics, allowing for a more thorough knowledge of disease mechanisms and the identification of new therapeutic targets.
However, the market faces ethical and legal problems with whole exome sequencing, particularly in terms of data protection, informed consent, and the interpretation of accidental results. To address these problems, industry stakeholders, governments, and healthcare practitioners must work together to develop clear rules and standards for the safe use of WES in research and clinical settings.
The increasing use of cloud-based data analysis platforms, as well as the integration of artificial intelligence and machine learning technologies, are expected to transform the WES data interpretation process, allowing for faster and more accurate identification of disease-causing variants and prediction of their functional impact. The creation of user-friendly and clinician-oriented WES reporting tools will be critical to the widespread adoption of WES in clinical practice.
As the market evolves, companies must focus on developing cost-effective and scalable WES solutions, forming strong partnerships with healthcare providers and research institutions, and investing in data security and privacy measures to foster trust and confidence in the technology.
Major Players:
-
Illumina, Inc.
-
Thermo Fisher Scientific, Inc.
-
Agilent Technologies, Inc.
-
Hoffmann-La Roche Ltd.
-
Qiagen N.V.
-
Beijing Genomics Institute (BGI)
-
Novogene Co., Ltd.
-
Macrogen, Inc.
-
Personalis, Inc.
-
Eurofins Scientific SE
Key Developments:
-
In January 2024, Illumina, Inc. introduced the Illumina DNA Prep with Exome 2.0, a new whole exome sequencing kit that provides better target coverage and a faster workflow for WES applications.
-
In August 2023, Thermo Fisher Scientific, Inc. engaged into a strategic agreement with a top healthcare provider to build a network of clinical WES testing facilities across the United States, with the goal of improving access to genetic testing for rare diseases.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium) *
5. COMPANY PROFILES
5.1. Illumina, Inc.
5.2. Thermo Fisher Scientific, Inc.
5.3. Agilent Technologies, Inc.
5.4. Hoffmann-La Roche Ltd.
5.5. Qiagen N.V.
5.6. Beijing Genomics Institute (BGI)
5.7. Novogene Co., Ltd.
5.8. Macrogen, Inc.
5.9. Personalis, Inc.
5.10. Eurofins Scientific SE (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Growing adoption of WES in clinical diagnostics
6.1.2. Integration of WES with other omics technologies
6.1.3. Increasing use of cloud-based data analysis platforms
6.2. Market Drivers
6.2.1. Advancements in sequencing technologies and data analysis
6.2.2. Growing demand for personalized medicine
6.2.3. Decreasing cost of whole exome sequencing
6.3. Market Restraints
6.3.1. Ethical and regulatory challenges associated with WES
6.3.2. Lack of standardized guidelines for WES data interpretation and reporting
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Kits
7.2. Systems & Software
7.3. Services
8. BY TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Sequencing by Synthesis
8.2. Ion Semiconductor Sequencing
8.3. Others
9. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Diagnostics
9.2. Drug Discovery & Development
9.3. Personalized Medicine
9.4. Agriculture & Animal Research
10. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospitals & Clinics
10.2. Pharmaceutical & Biotechnology Companies
10.3. Academics & Research Institutes
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. US
11.1.2. Canada
11.2. Europe
11.2.1. Germany
11.2.2. UK
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of APAC
11.4. Latin America
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Middle East & Africa
11.5.1. South Africa
11.5.2. GCC Countries
11.5.3. Rest of EMEA
*NOTE: All the segments mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Whole Exome Sequencing [WES] Market Segmentation:
By Product:
-
Kits
-
Systems & Software
-
Services
By Technology:
-
Sequencing by Synthesis
-
Ion Semiconductor Sequencing
-
Others
By Application:
-
Diagnostics
-
Drug Discovery & Development
-
Personalized Medicine
-
Agriculture & Animal Research
By End User:
-
Hospitals & Clinics
-
Pharmaceutical & Biotechnology Companies
-
Academics & Research Institutes
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511